Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis.
作者信息
Saeed Anzel, Rai Kuldeep Dalpat, Saeed Muzammil
机构信息
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Department of Medicine, Karachi Medical and Dental College, Karachi Metropolitan University, Karachi, Pakistan.
出版信息
Liver Res. 2024 Jul 14;8(3):193-194. doi: 10.1016/j.livres.2024.07.002. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis.
Liver Res. 2024 Jul 14;8(3):193-194. doi: 10.1016/j.livres.2024.07.002. eCollection 2024 Sep.
2
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
3
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
4
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals.
Curr Obes Rep. 2024 Dec;13(4):818-830. doi: 10.1007/s13679-024-00582-z. Epub 2024 Aug 7.
5
Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis.
Eur J Gastroenterol Hepatol. 2025 Apr 1;37(4):395-402. doi: 10.1097/MEG.0000000000002901. Epub 2024 Dec 3.
6
The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5.
7
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.
Hepatology. 2025 Apr 1;81(4):1318-1327. doi: 10.1097/HEP.0000000000001084. Epub 2024 Sep 6.
8
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.
9
Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting.
Hepatol Commun. 2025 Apr 3;9(4). doi: 10.1097/HC9.0000000000000670. eCollection 2025 Apr 1.
10
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom.
Curr Issues Mol Biol. 2025 Feb 27;47(3):154. doi: 10.3390/cimb47030154.
引用本文的文献
1
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.
Cell Mol Immunol. 2025 Jun 10. doi: 10.1038/s41423-025-01307-5.
2
Unlocking the potential of THR-β agonist therapies: resmetirom's chemistry, biology, and patent insights.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9703-9720. doi: 10.1007/s00210-025-03880-y. Epub 2025 Mar 11.
本文引用的文献
1
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
Endocr Pract. 2024 Jul;30(7):631-638. doi: 10.1016/j.eprac.2024.04.016. Epub 2024 May 1.
2
The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Medicine (Baltimore). 2024 Feb 16;103(7):e37271. doi: 10.1097/MD.0000000000037271.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
N Engl J Med. 2017 Nov 23;377(21):2063-2072. doi: 10.1056/NEJMra1503519.
5
Pharmacotherapy for NASH: Current and emerging.
J Hepatol. 2018 Feb;68(2):362-375. doi: 10.1016/j.jhep.2017.10.015. Epub 2017 Nov 6.
6
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
7
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
8
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
Zotero 插件